Literature DB >> 26344541

Point-of-care D-dimer testing in emergency departments.

Udo Marquardt1, Daniel Apau2.   

Abstract

Overcrowding and prolonged patient stays in emergency departments (EDs) affect patients' experiences and outcomes, and increase healthcare costs. One way of addressing these problems is through using point-of-care blood tests, laboratory testing undertaken near patient locations with rapidly available results. D-dimer tests are used to exclude venous thromboembolism (VTE), a common presentation in EDs, in low-risk patients. However, data on the effects of point-of-care D-dimer testing in EDs and other urgent care settings are scarce. This article reports the results of a literature review that examined the benefits to patients of point-of-care D-dimer testing in terms of reduced turnaround times (time to results), and time to diagnosis, discharge or referral. It also considers the benefits to organisations in relation to reduced ED crowding and increased cost effectiveness. The review concludes that undertaking point-of-care D-dimer tests, combined with pre-test probability scores, can be a quick and safe way of ruling out VTE and improving patients' experience.

Entities:  

Keywords:  deep venous thrombosis; emergency department; point-of-care D-dimer; pulmonary embolism; turnaround times; urgent care centre; venous thromboembolism

Mesh:

Substances:

Year:  2015        PMID: 26344541     DOI: 10.7748/en.23.5.29.e1459

Source DB:  PubMed          Journal:  Emerg Nurse        ISSN: 1354-5752


  2 in total

1.  Modern diagnostics in emergency medicine.

Authors:  Jan Niederdöckl; Nina Buchtele; Michael Schwameis; Hans Domanovits
Journal:  Wien Klin Wochenschr       Date:  2021-03       Impact factor: 1.704

Review 2.  Detection of COVID-19-related biomarkers by electrochemical biosensors and potential for diagnosis, prognosis, and prediction of the course of the disease in the context of personalized medicine.

Authors:  Viviana Vásquez; Jahir Orozco
Journal:  Anal Bioanal Chem       Date:  2022-08-16       Impact factor: 4.478

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.